JP2021513960A5 - - Google Patents

Info

Publication number
JP2021513960A5
JP2021513960A5 JP2020542852A JP2020542852A JP2021513960A5 JP 2021513960 A5 JP2021513960 A5 JP 2021513960A5 JP 2020542852 A JP2020542852 A JP 2020542852A JP 2020542852 A JP2020542852 A JP 2020542852A JP 2021513960 A5 JP2021513960 A5 JP 2021513960A5
Authority
JP
Japan
Prior art keywords
sequence
seq
bone
gremlin
inhibitor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2020542852A
Other languages
English (en)
Japanese (ja)
Other versions
JP2021513960A (ja
JP7395485B2 (ja
Filing date
Publication date
Priority claimed from GBGB1802486.9A external-priority patent/GB201802486D0/en
Application filed filed Critical
Publication of JP2021513960A publication Critical patent/JP2021513960A/ja
Publication of JP2021513960A5 publication Critical patent/JP2021513960A5/ja
Application granted granted Critical
Publication of JP7395485B2 publication Critical patent/JP7395485B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2020542852A 2018-02-15 2019-02-14 骨折又は骨欠損の処置のためのグレムリン-1阻害剤 Active JP7395485B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1802486.9 2018-02-15
GBGB1802486.9A GB201802486D0 (en) 2018-02-15 2018-02-15 Methods
PCT/EP2019/053726 WO2019158658A1 (en) 2018-02-15 2019-02-14 Gremlin-1 inhibitor for the treatment of a bone fracture or bone defect

Publications (3)

Publication Number Publication Date
JP2021513960A JP2021513960A (ja) 2021-06-03
JP2021513960A5 true JP2021513960A5 (https=) 2022-02-21
JP7395485B2 JP7395485B2 (ja) 2023-12-11

Family

ID=61783877

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2020542852A Active JP7395485B2 (ja) 2018-02-15 2019-02-14 骨折又は骨欠損の処置のためのグレムリン-1阻害剤

Country Status (17)

Country Link
US (2) US11524997B2 (https=)
EP (1) EP3752527A1 (https=)
JP (1) JP7395485B2 (https=)
KR (1) KR20200121833A (https=)
CN (1) CN111683965B (https=)
AR (1) AR114105A1 (https=)
AU (1) AU2019220407B2 (https=)
BR (1) BR112020015961A2 (https=)
CA (1) CA3090404A1 (https=)
CL (2) CL2020002040A1 (https=)
CO (1) CO2020009731A2 (https=)
EA (1) EA202091891A1 (https=)
GB (1) GB201802486D0 (https=)
IL (1) IL276491A (https=)
MX (1) MX2020007431A (https=)
SG (1) SG11202005735SA (https=)
WO (1) WO2019158658A1 (https=)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201621635D0 (en) 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
MX2020013808A (es) 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.
WO2022084400A1 (en) 2020-10-20 2022-04-28 Kantonsspital St. Gallen Antibodies or antigen-binding fragments specifically binding to gremlin-1 and uses thereof
US20250257123A1 (en) 2022-04-20 2025-08-14 Kantonsspital St. Gallen Antibodies or antigen-binding fragments pan-specifically binding to gremlin-1 and gremlin-2 and uses thereof
CN121399151A (zh) * 2023-05-26 2026-01-23 香港大学 用于治疗骨质流失的组合物和方法
WO2026027660A1 (en) 2024-08-02 2026-02-05 UCB Biopharma SRL Formulations of anti-gremlin-1 antibodies

Family Cites Families (57)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8422238D0 (en) 1984-09-03 1984-10-10 Neuberger M S Chimeric proteins
DK336987D0 (da) 1987-07-01 1987-07-01 Novo Industri As Immobiliseringsmetode
GB8719042D0 (en) 1987-08-12 1987-09-16 Parker D Conjugate compounds
GB8720833D0 (en) 1987-09-04 1987-10-14 Celltech Ltd Recombinant dna product
EP0436597B1 (en) 1988-09-02 1997-04-02 Protein Engineering Corporation Generation and selection of recombinant varied binding proteins
US5223409A (en) 1988-09-02 1993-06-29 Protein Engineering Corp. Directed evolution of novel binding proteins
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
GB8907617D0 (en) 1989-04-05 1989-05-17 Celltech Ltd Drug delivery system
GB8928874D0 (en) 1989-12-21 1990-02-28 Celltech Ltd Humanised antibodies
US5859205A (en) 1989-12-21 1999-01-12 Celltech Limited Humanised antibodies
US5780225A (en) 1990-01-12 1998-07-14 Stratagene Method for generating libaries of antibody genes comprising amplification of diverse antibody DNAs and methods for using these libraries for the production of diverse antigen combining molecules
AU7247191A (en) 1990-01-11 1991-08-05 Molecular Affinities Corporation Production of antibodies using gene libraries
DE69120146T2 (de) 1990-01-12 1996-12-12 Cell Genesys Inc Erzeugung xenogener antikörper
US5427908A (en) 1990-05-01 1995-06-27 Affymax Technologies N.V. Recombinant library screening methods
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
CA2090126C (en) 1990-08-02 2002-10-22 John W. Schrader Methods for the production of proteins with a desired function
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
ATE158021T1 (de) 1990-08-29 1997-09-15 Genpharm Int Produktion und nützung nicht-menschliche transgentiere zur produktion heterologe antikörper
US5698426A (en) 1990-09-28 1997-12-16 Ixsys, Incorporated Surface expression libraries of heteromeric receptors
CA2095633C (en) 1990-12-03 2003-02-04 Lisa J. Garrard Enrichment method for variant proteins with altered binding properties
ATE414768T1 (de) 1991-04-10 2008-12-15 Scripps Research Inst Bibliotheken heterodimerer rezeptoren mittels phagemiden
GB9112536D0 (en) 1991-06-11 1991-07-31 Celltech Ltd Chemical compounds
GB9113120D0 (en) 1991-06-18 1991-08-07 Kodak Ltd Photographic processing apparatus
GB9120467D0 (en) 1991-09-26 1991-11-06 Celltech Ltd Anti-hmfg antibodies and process for their production
PT1024191E (pt) 1991-12-02 2008-12-22 Medical Res Council Produção de auto-anticorpos a partir de reportórios de segmentos de anticorpo e exibidos em fagos
US5733743A (en) 1992-03-24 1998-03-31 Cambridge Antibody Technology Limited Methods for producing members of specific binding pairs
WO1995015982A2 (en) 1993-12-08 1995-06-15 Genzyme Corporation Process for generating specific antibodies
DE69534347T2 (de) 1994-01-31 2006-05-24 Trustees Of Boston University, Boston Bibliotheken aus Polyklonalen Antikörpern
FR2716640B1 (fr) 1994-02-28 1996-05-03 Procedes Machines Speciales Dispositif de centrage et de blocage d'une pièce en vue de son rodage à l'aide d'un rodoir à expansion.
US5516637A (en) 1994-06-10 1996-05-14 Dade International Inc. Method involving display of protein binding pairs on the surface of bacterial pili and bacteriophage
JP2978435B2 (ja) 1996-01-24 1999-11-15 チッソ株式会社 アクリロキシプロピルシランの製造方法
GB9625640D0 (en) 1996-12-10 1997-01-29 Celltech Therapeutics Ltd Biological products
EP1053002A1 (en) 1998-02-10 2000-11-22 Oregon Health Sciences University Treatment of bony defects with osteoblast precursor cells
WO2002054940A2 (en) 2001-01-12 2002-07-18 University Of Medicine & Dentistry Of New Jersey Bone morphogenetic protein-2 in the treatment and diagnosis of cancer
US6908963B2 (en) 2001-10-09 2005-06-21 Nektar Therapeutics Al, Corporation Thioester polymer derivatives and method of modifying the N-terminus of a polypeptide therewith
ES2374068T3 (es) 2002-12-03 2012-02-13 Ucb Pharma, S.A. Ensayo para identificar células productoras de anticuerpos.
GB0312481D0 (en) 2003-05-30 2003-07-09 Celltech R&D Ltd Antibodies
ES2551439T5 (es) 2003-07-01 2018-11-08 Ucb Biopharma Sprl Fragmentos Fab de anticuerpos modificados
GB0315450D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
GB0315457D0 (en) 2003-07-01 2003-08-06 Celltech R&D Ltd Biological products
EP2824190A1 (en) 2003-09-09 2015-01-14 Integrigen, Inc. Methods and compositions for generation of germline human antibody genes
EP1571159A1 (en) 2004-03-04 2005-09-07 Bayerische Julius-Maximilians-Universität Würzburg Mutein of a bone morphogenetic protein and use thereof
GB0411186D0 (en) 2004-05-19 2004-06-23 Celltech R&D Ltd Biological products
GB0412181D0 (en) 2004-06-01 2004-06-30 Celltech R&D Ltd Biological products
US20090203041A1 (en) 2006-04-21 2009-08-13 Wei Shi Bmp4 inhibitors
GB0619291D0 (en) 2006-09-29 2006-11-08 Ucb Sa Altered antibodies
US8383349B2 (en) 2007-03-16 2013-02-26 The Board Of Trustees Of The Leland Stanford Junior University Bone morphogenetic protein antagonist and uses thereof
EP2535349A1 (en) 2007-09-26 2012-12-19 UCB Pharma S.A. Dual specificity antibody fusions
EP2826790B1 (en) * 2012-03-15 2019-02-13 SNU R&DB Foundation Anti-gremlin-1 antibody
EA201591762A1 (ru) 2013-03-14 2015-12-30 Ридженерон Фармасьютикалз, Инк. Человеческие антитела к grem1
GB201621635D0 (en) * 2016-12-19 2017-02-01 Ucb Biopharma Sprl Crystal structure
GB201802486D0 (en) 2018-02-15 2018-04-04 Ucb Biopharma Sprl Methods
MX2020013808A (es) 2018-06-18 2021-05-27 UCB Biopharma SRL Antagonista de gremlina-1 para la prevencion y el tratamiento del cancer.

Similar Documents

Publication Publication Date Title
JP2021513960A5 (https=)
JP2023002562A5 (https=)
JP2021521843A5 (https=)
AR126019A1 (es) Anticuerpos frente a entpd2, terapias de combinación y métodos de uso de los anticuerpos y las terapias de combinación
JP2024020298A5 (https=)
RU2011105062A (ru) Нейтрализующие антитела против вируса гриппа а и их использование
JP2023515271A5 (https=)
JP2022031635A5 (https=)
JP2025131696A5 (https=)
PE20210132A1 (es) Anticuerpos anti-cd3 y usos de estos
RU2013155906A (ru) Антитела анти-angptl3 и их применение
JP2019513751A5 (https=)
IL276695A (en) Antibodies, pharmaceutical compositions and uses thereof
JP2016538876A5 (https=)
JP2013542194A5 (https=)
RU2017134495A (ru) Антитела к альфа-рецептору собачьего интерлейкина-4
RU2014148502A (ru) Человеческие антитела к fel d1 и способы их применения
JP2017512759A5 (https=)
IL312710A (en) Methods for treating allergy and enhancing allergen-specific immunotherapy by administering an il-4r inhibitor
RU2020130795A (ru) Нейтрализующие антитела к env вич-1 и их применение
JP2020511946A5 (https=)
JP2016513682A5 (https=)
NZ595011A (en) Humanised antibodies that bind and inhibit human DKK-1 protein and composition containing antibodies for treating DKK-1 associated diseases
RU2012103212A (ru) Tlr3 связывающие агенты
JP2024024114A5 (https=)